Autonomix Medical (AMIX) Q3 2026 earnings summary

Executive summary

• Focused on developing a catheter-based platform for sensing and treating nervous system disorders, with initial applications in pancreatic cancer pain and broader potential in cardiology and chronic pain.

• Completed first-in-human proof-of-concept study and initiated a follow-on clinical trial expanding to additional cancer pain indications.

• Issued new U.S. and European patents strengthening intellectual property for nerve-targeted therapies in cardiology.

• Raised $5.0 million in a private placement in November 2025 and implemented a reverse stock split as approved by shareholders.

Financial highlights

• No revenue generated for the three and nine months ended December 31, 2025 and 2024.

• Net loss of $3.3 million for the quarter and $14.0 million for the nine months ended December 31, 2025, compared to $2.7 million and $8.2 million for the same periods in 2024.

• Operating expenses increased to $3.3 million for the quarter and $14.3 million for the nine months, up 22% and 72% year-over-year, respectively.

• Cash and cash equivalents were $9.9 million as of December 31, 2025, with working capital of $8.5 million.

• Net cash used in operating activities was $9.4 million for the nine months ended December 31, 2025.

Outlook and guidance

• Current cash resources are expected to fund operations into, but not beyond, the third calendar quarter of 2026.

• Additional financing of $30–36 million estimated to be required to reach commercialization of the first indication.

• Ongoing need to raise capital to support clinical trials, regulatory clearance, and commercialization.